In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Latest From Ipsen SA

Novo Holdings’ Jee On Korea's Potential As Next Global Biotech Player

In this video interview, Novo Holdings’ Noel Jee shares his views on the Korean biotech industry and innovation, including how to draw more foreign investment into the sector.

South Korea Innovation

Exelixis’s Cabometyx Two-For-Two In A Week As Neuroendocrine Tumor Study Hits Endpoint

The announcement of the CABINET study’s success follows by days positive results for CONTACT-02 in prostate cancer, though NETs represent a smaller commercial opportunity.

Clinical Trials Cancer

Ipsen’s Cabometyx Bounces Back With Promising Pivotal Prostate Cancer Results

The French drugmaker’s tyrosine kinase inhibitor has met the progression-free survival primary endpoint in combination with Roche’s Tecentriq in a metastatic prostate cancer trial, edging closer to a large market opportunity after a trio of recent failures in other indications.

Clinical Trials ImmunoOncology

Keeping Track: Pfizer And J&J’s Dueling Myeloma Bispecifics; Regeneron And Ipsen Nab Priority Vouchers

Shared REMS, diverse confirmatory trials and manufacturing delays are among the highlights in the latest US FDA drug approval news from the Pink Sheet’s US FDA Performance Tracker.

US FDA Performance Tracker Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • OTC, Consumer
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Clementia Pharmaceuticals, Inc.
    • Epizyme, Inc.
    • Ipsen Bioscience, Inc.
    • Sterix
    • Tercica, Inc.
    • Syntaxin Ltd.
    • OctreoPharm Sciences GmbH
    • Octagen Corporation